Research Paper Volume 16, Issue 1 pp 226—245

Figure 6. Predictive role of RBMX and its relationships with immune regulators, TMB, and MSI. (A) Correlations of RBMX expression with 47 types of immune regulators in the pan-cancer setting, illustrated by the Spearman correlation analysis. Red and blue squares represent positive and negative correlations, respectively. (B) Correlations between RBMX expression and MSI in the pan-cancer setting. (C) Correlations between RBMX expression and TMB in the pan-cancer setting. (D) Low- and high-RBMX subgroups distinguished based on the Kaplan–Meier curves in the Gide2019 cohort (anti-CTLA-4 and anti-PD-1, melanoma). Proportion of patients with melanoma who responded to anti-CTLA-4 and anti-PD-1 therapy in the low- and high-RBMX subgroups of the IMvigor210 cohort. (E) Low- and high-RBMX subgroups distinguished based on the Kaplan–Meier curves in the Riaz2017 cohort (anti-PD-1, melanoma). Proportion of patients with melanoma who responded to anti-PD-1 therapy in the low- and high-RBMX subgroups of the IMvigor210 cohort. (F) Low- and high-RBMX subgroups distinguished based on the Kaplan–Meier curves in the Lauss2017 cohort (ACT, melanoma). Proportion of patients with melanoma who responded to ACT therapy in the low- and high-RBMX subgroups of the IMvigor210 cohort. (G) Low- and high-RBMX subgroups distinguished based on the Kaplan–Meier curves in the Vanallen2015 cohort (anti-CTLA-4, melanoma). Proportion of patients with melanoma who responded to ACT therapy in the low- and high-RBMX subgroups of the IMvigor210 cohort. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate statistical significance. ACT, adoptive cell transfer therapy; CTLA-4, cytotoxic T-lymphocyte associated protein 4; MSI, microsatellite instability; PD-1, programmed cell death-1; RBMX, RNA binding motif protein X-linked; TMB, tumor mutation burden.